Jove
Visualize
Contact Us

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

221
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
221
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

132
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
132
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

200
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
200
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding the Molecular Landscape of Alopecia Areata: Key Genes, Regulatory Networks, and Therapeutic Targets.

Health science reports·2026
Same author

Genetic susceptibility and HLA association in autoimmune hepatitis among Yemeni patients.

BMC immunology·2026
Same author

Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation.

Health science reports·2026
Same author

Evaluation of Oxidative Stress in Red Blood Cells From Vitiligo Patients and Its Correlation With Disease Severity and Activity: A Cohort Case-Control Study.

Health science reports·2026
Same author

Expression of multidrug efflux pump gene acrAB in Escherichia coli: a systematic review and meta analysis.

BMC infectious diseases·2025
Same author

Characterization of Genetic and Chemical Drivers in the Pathogenesis of DRESS Syndrome: In Silico Study.

Health science reports·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:27

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

686

Tirzepatide Affect Sexual Function in Women: Case Report.

Ghada Farouk Mohammed1, Mohammed Saleh Al-Dhubaibi2, Saleh Salem Bahaj3

  • 1Department of Dermatology, Venereology and Sexology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Clinical Medicine Insights. Case Reports
|June 9, 2025
PubMed
Summary

Tirzepatide, a dual GIP/GLP-1 receptor agonist, may cause sexual dysfunction in some patients. Symptoms resolved upon discontinuation and reappeared upon reinitiation, suggesting a drug-related effect requiring further investigation.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Sexual Medicine

Background:

  • Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control.
Keywords:
FSFIobesitysexual drivetirzepatide

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.1K

Related Experiment Videos

Last Updated: Jun 12, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:27

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

686
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.1K
  • While effective for weight management and type 2 diabetes, its potential adverse effects on sexual function are not well-documented.